Mon, May 12, 9:39 PM (39 days ago)
**Mineralys Therapeutics, Inc. (MLYS) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** No revenue generated; the company is in the clinical-stage and has not yet commercialized any products. - **Net Loss:** $42.2 million for Q1 2025, up from $31.5 million in Q1 2024, due to increased research and development (R&D) and general and administrative (G&A) expenses. - **Operating Expenses:** Total operating expenses were $44.4 million, with R&D expenses at $37.9 million and G&A expenses at $6.6 million. - **Cash Flow:** Net cash used in operating activities was $45.5 million, while net cash provided by financing activities was $189.3 million, primarily from a public offering of common stock. - **Cash Position:** As of March 31, 2025, the company had $343.0 million in cash, cash equivalents, and investments. **Key Metrics and Trends:** - **Profit Margins:** Not applicable due to lack of revenue. - **Earnings Changes:** Net loss per share increased to $0.79 from $0.70 in the previous year. - **Quarterly Performance:** The company is in the development stage, focusing on clinical trials and regulatory approvals. - **Uncertainties:** Dependence on successful clinical trials, regulatory approvals, and future financing. **Future Operations and Impact:** - **Clinical Trials:** Ongoing and planned trials for lorundrostat in hypertension, chronic kidney disease, and obstructive sleep apnea. - **Regulatory:** Anticipating a pre-NDA meeting with the FDA in Q4 2025 for lorundrostat. - **Financing:** Plans to finance operations through equity offerings, debt financings, and potential collaborations. **Summary:** Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing lorundrostat for cardiorenal conditions. The company reported increased losses in Q1 2025 due to higher R&D and G&A expenses. Despite the lack of revenue, the company has a strong cash position and is advancing its clinical programs. Future performance will depend on successful clinical trials, regulatory approvals, and securing additional financing.